Mantle cell lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 2: Line 2:
{{Mantle cell lymphoma }}
{{Mantle cell lymphoma }}


{{CMG}}; {{AE}} {{AS}}
{{CMG}}; {{AE}} {{Akram}}


==Overview==
==Overview==
Line 16: Line 16:
:* Targeted therapy using newer biological agents  
:* Targeted therapy using newer biological agents  
:* Stem cell transplantation  
:* Stem cell transplantation  
===Chemotherapy===
[[Chemotherapy]] is predominantly used as frontline treatment, and is usually not repeated in relapse due to high risk of adverse effects. Alternate chemotherapeutic regimens, however, are sometimes used upon first relapse.<ref>http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf</ref>
* Frontline treatment
:* Drug Regimen: [[CHOP]] (IV) ([[Cyclophosphamide]] {{and}} [[Doxorubicin]] {{and}} [[Vincristine]] {{and}} [[Prednisone]]) {{plus}} [[Rituximab]] 
:* Drug Regimen: [[Fludarabine]]
:* Drug Regimen: [[Fludarabine]] {{withorwithout}} ([[Cyclophosphamide]] {{and}} [[Mitoxantrone]] {{and}} [[Rituximab]])
* Elderly (over 65) patients
:* Drug Regimen:
::*Hyper-(CVAD) Course A:[[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]]
::*Hyper-(VCAD) Course B: [[Methotrexate]] {{and}} [[Cytarabine]]
===Immunotherapy===
*[[Rituximab]] is a monoclonal antibody that is effective against mantle cell lymhpma. It may be used in combination with other chemotherapeutic regimens to prolong response duration. Rituximab tags the cancer cells for destruction by the body.
*Other variations of monoclonal antibodies combined with radioactive molecules include [[Radioimmunotherapy]] (RIT), such as Zevalin and [[Bexxar]].
===Targeted Therapy===
Targeted agents include the proteasome inhibitor [[Velcade]] and mTor (mammalian target of rapamycin) inhibitors such as [[Torisel|temsirolimus]].


==References==
==References==

Revision as of 18:53, 19 December 2018

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma medical therapy

on Mantle cell lymphoma medical therapy

Mantle cell lymphoma medical therapy in the news

Blogs on Mantle cell lymphoma medical therapy

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

The mainstay of treatment for mantle cell lymphoma is chemotherapy. However, immunotherapy, radioimmunotherapy, targeted therapy using newer biological agents and stem cell transplantation are also used along with chemotherapy to treat the disease. Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncology specialists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

Medical Therapy

Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncology specialists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

  • Different types of treatment currently being used to treat mantle cell lymphoma are as follows:

References

Template:Hematology

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mantle_cell_lymphoma_medical_therapy&oldid=1510832"